Details

Autor(en) / Beteiligte

• Rangé, G
• Hakim, R
• Etienne, C Saint
• Deballon, R
• Dechery, T
• Souteyrand, G
• Bar, O
• Albert, F
• Canville, A
• Gamet, A
• Beygui, F
• Viallard, L
• Bonnet, P
• Durand, E
• Lesault, P-F
• Boiffard, E
• Koning, R
• Benamer, H
• Commeau, P
• Cayla, G
• Motreff, P

Titel

stent thrombosis : A won battle ? (data from the France PCI registry)

Ist Teil von

• Annales de cardiologie et d'angeiologie, 2021-12, Vol.70 (6), p.388-394

Ort / Verlag

France

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of the study is to assess the incidence, risk factors and prognosis of definite stent thrombosis (ST) at 1 year in the France PCI multicenter prospective registry. Only patients who underwent coronary angioplasty with at least one stent implantation between 1 January 2014 and 31 December 2019 were included. The population was separated into 2 groups: the "ST" group with stent thrombosis and the "control" group without stent thrombosis. 35,435 patients were included. 256 patients (0.72%) presented a ST at 1 year. The rate of ST decreased significantly in acute coronary syndrome (1.5% in 2014 vs. 0.73% in 2019; p = 0.05) but not in chronic coronary syndrome (0.46% in 2014 vs 0.40%; p = 0.98). The risk factors are young age (65.8 years vs 68.2; p = 0.002), clinical context (35.27% vs 16.68%; p = 0.0001), diabetes (35.2 % vs 26.4%; p = 0.002), renal failure (11.7% vs 8%; p = 0.009) and history of coronary angioplasty (28.63% vs 21.86%; p = 0.009) and peripheral arterial disease (14.5% vs 10.1%; p = 0.021), LV dysfunction (37% vs 27.5%; p = 0.003), mean length (39.6 mm vs 31, 7mm; p <0.0001) and the mean number of stents per procedure (1.9 vs 1.6; p <0.0001), a TIMI flow ≤1 pre procedure (21.5% vs 12.4%; p <0.0001) and an intrastent restenosis (11% vs 6%; p <0.0001). The 1-year mortality of the ST group was significantly higher than that of the control group (19.14% vs 5.82%; p <0.0001). Since 2014, the incidence of ST at 1 year has been decreasing but remains stuck at a floor level of 0.54% in 2019. The battle for ST seems to have been partly won and its risk factors well identified, but its mortality is still high.